Search Results - "Burris HA"

Efficacy and Safety of Ribociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR-Positive/HER2-Negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors: Dhungana, Reechashree Prasai, Parikshit Paudel, Bishal et al.

Source: Clinical Medicine Insights: Oncology. 12/18/2025, Vol. 19, p1-9. 9p.

Real world experience with cyclin dependent kinase inhibitors in metastatic breast cancer in India.

Authors: Mukherjee, Anindya Goyal, Pankaj Tripathi, Rupal et al.

Source: PLoS ONE. 5/15/2026, Vol. 21 Issue 5, p1-11. 11p.

Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance.

Authors: Schneider, Julia S. Khaled, Najib Ben Ye, Liangtao et al.

Source: Cellular Oncology (2211-3428). Oct2025, Vol. 48 Issue 5, p1363-1375. 13p.

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer.

Authors: Singareeka Raghavendra A Damodaran S Barcenas CH et al.

Source: CA: a cancer journal for clinicians [CA Cancer J Clin] 2026 Jan-Feb; Vol. 76 (1), pp. e70055.

Publication Type: Journal Article; Review

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0370647 Publication Model: Print Cited Medium: Internet ISSN: 1542-4863 (Electronic) Linking ISSN: 00079235 NLM ISO Abbreviation: CA Cancer J Clin Subsets: MEDLINE

Treatment Outcomes in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer Patients with and without Progression after Completion of Reimbursed Cyclin-dependent Kinase 4/6 Inhibitors in Taiwan: A Single-institution Experience.

Authors: Hsu, Yi-Hsuan Yang, Po-Shen Chang, Yuan-Ching et al.

Source: Journal of Cancer Research & Practice. Jan-Mar2026, Vol. 13 Issue 1, p9-17. 9p.

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.

Authors: Karacin, Cengiz Oksuzoglu, Berna Demirci, Ayşe et al.

Source: BMC Cancer. 2/13/2023, Vol. 23 Issue 1, p1-10. 10p.

Research trends and hot spots in the prevention and management of radiation dermatitis: a bibliometric analysis based on CiteSpace.

Authors: Zhang, Lu Liu, Lian Li, Fang et al.

Source: Radiation Oncology. 4/16/2025, Vol. 20 Issue 1, p1-13. 13p.

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Authors: Gounder M Johnson M Heist RS et al.

Source: Nature communications [Nat Commun] 2025 Jan 06; Vol. 16 (1), pp. 423. Date of Electronic Publication: 2025 Jan 06.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Cutaneous Skin Toxicities of Oncological Targeted Therapies: Comprehensive Overview of Mechanisms, Management, and Research Gaps—A Narrative Review.

Authors: Janicki, Piotr Makowska, Anna Jakubczyk-Słabicka, Anna et al.

Source: Dermatology & Therapy. Apr2026, Vol. 16 Issue 4, p1847-1868. 22p.

Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma.

Authors: Wong, Lindsay Nwosu, Chisom Nadora, Denise et al.

Source: Clinical & Translational Discovery. Apr2026, Vol. 6 Issue 2, p1-13. 13p.

First-Line Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Real-World Outcomes and Prognostic Factors From a Vietnamese Cohort.

Authors: Nguyen, Huy Van Dinh, Phuong Thi Tran, Thang et al.

Source: Clinical Medicine Insights: Oncology. 2/25/2026, Vol. 20, p1-8. 8p.

Surufatinib plus anti‐PD‐1/PD‐L1 antibody as second‐line therapy for advanced biliary tract cancer: A single‐centre investigator‐initiated trial.

Authors: Chen, Xinni Wang, Feng Cheng, Yuan et al.

Source: Clinical & Translational Discovery. Feb2026, Vol. 6 Issue 1, p1-11. 11p.

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer.

Authors: Ji Y Wang C Combes FP et al.

Source: Clinical pharmacokinetics [Clin Pharmacokinet] 2026 Jun 23. Date of Electronic Publication: 2026 Jun 23.

Publication Type: Journal Article

Journal Info: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE

Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

Authors: Pernas S Forns X Martínez-Sáez O et al.

Source: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2026 May 10. Date of Electronic Publication: 2026 May 10.

Publication Type: Journal Article; Review

Journal Info: Publisher: Springer Italia Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

Differential Efficacy of Alpelisib by PIK3CA Mutation Site in Head and Neck Squamous Cell Carcinoma: An Analysis from the KCSG HN 15-16 TRIUMPH Trial.

Authors: Kim, Kyoo Hyun Hwang, Shinwon Kim, Min Kyoung et al.

Source: Cancer Research & Treatment. Oct2025, Vol. 57 Issue 4, p968-980. 13p.

Geriatric Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2024.

Authors: Wolf, Clemens Wedding, Ulrich

Source: Oncology Research & Treatment. 2025, Vol. 48 Issue 9, p558-562. 4p.

A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.

Authors: Sreenath, Nihanthy D. Pandalanghat, Suresh Kapoor, Amul et al.

Source: BMC Cancer. 8/18/2025, Vol. 25 Issue 1, p1-9. 9p.

Hand-Foot Syndrome as a Rare Side Effect of Bleomycin.

Authors: Hashmi, Aateqa Abid, Maryam Zafar, Amjad et al.

Source: Pakistan Journal of Medical Sciences. Jul2026, Vol. 42 Issue 7, p1900-1902. 3p.

The evolving landscape of tissue-agnostic therapies in precision oncology.

Authors: Subbiah V Gouda MA Ryll B et al.

Source: CA: a cancer journal for clinicians [CA Cancer J Clin] 2024 Sep-Oct; Vol. 74 (5), pp. 433-452. Date of Electronic Publication: 2024 May 30.

Publication Type: Journal Article; Review; Research Support, N.I.H., Extramural

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0370647 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-4863 (Electronic) Linking ISSN: 00079235 NLM ISO Abbreviation: CA Cancer J Clin Subsets: MEDLINE

Target-Enhanced Whole-Genome Sequencing Shows Clinical Validity Equivalent to Commercially Available Targeted Oncology Panel.

Authors: Lee, Sangmoon Roh, Jin Park, Jun Sung et al.

Source: Cancer Research & Treatment. Apr2025, Vol. 57 Issue 2, p350-361. 12p.